This HTML5 document contains 148 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-dehttp://de.dbpedia.org/resource/
dctermshttp://purl.org/dc/terms/
n25http://elan.com/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
dbpedia-sqhttp://sq.dbpedia.org/resource/
n6https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
schemahttp://schema.org/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n24http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
n23http://viaf.org/viaf/
dbpedia-fahttp://fa.dbpedia.org/resource/
n18http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/
n21http://d-nb.info/gnd/

Statements

Subject Item
dbr:Élan
rdf:type
yago:Company108058098 yago:WikicatCompaniesBasedInDublin(city) yago:WikicatCompaniesOfIreland dbo:Organisation yago:Group100031264 yago:Organization108008335 yago:Abstraction100002137 yago:WikicatBiotechnologyCompanies wikidata:Q4830453 yago:Institution108053576 wikidata:Q43229 yago:SocialGroup107950920 schema:Organization yago:YagoPermanentlyLocatedEntity yago:YagoLegalActor yago:YagoLegalActorGeo dbo:Company dbo:Agent n24:SocialPerson owl:Thing wikidata:Q24229398 n24:Agent
rdfs:label
Elan Corporation Élan
rdfs:comment
Elan Corporation plc was a major drugs firm based in Dublin, Ireland, which had major interests in the United States. It was listed on the New York Stock Exchange as ELN, the Irish Stock Exchange as ELN.I, and the London Stock Exchange as ELN.L. In 2013, the company merged with Perrigo to form Perrigo Company PLC. Die Elan Corporation war ein irisch-amerikanisches Biotechunternehmen mit 400 Mitarbeiten (Stand 2012); Ende 2007 hatte die Firma 2000 Mitarbeiter. Elan hat sich auf Krankheiten des Zentralnervensystems wie Multiple Sklerose, Alzheimer-Krankheit und Parkinson-Krankheit spezialisiert, stellt aber auch Antibiotika her. Im Bereich der Alzheimer-Forschung arbeitet Elan an Inhibitoren der Gamma- und Beta-Sekretase, welche die Entstehung der Krankheit verhindern könnten. Das Unternehmen ist Mitglied im ISEQ Overall Index an der Irish Stock Exchange.
foaf:name
Elan Corporation plc
dbp:name
Elan Corporation plc
foaf:depiction
n18:Elan.png
dbo:location
dbr:Dublin
dcterms:subject
dbc:Manufacturing_companies_based_in_Dublin_(city) dbc:2013_disestablishments_in_Ireland dbc:2013_mergers_and_acquisitions dbc:Pharmaceutical_companies_disestablished_in_2013 dbc:Companies_formerly_listed_on_the_London_Stock_Exchange dbc:1969_establishments_in_Ireland dbc:Companies_formerly_listed_on_Euronext_Dublin dbc:Pharmaceutical_companies_of_Ireland dbc:Pharmaceutical_companies_established_in_1969 dbc:Companies_formerly_listed_on_the_New_York_Stock_Exchange dbc:Athlone
dbo:wikiPageID
654526
dbo:wikiPageRevisionID
1118106166
dbo:wikiPageWikiLink
dbr:Multiple_sclerosis dbr:Gamma_secretase dbr:Biogen_Idec dbr:Perrigo dbr:Euro dbr:Stock dbr:United_States_dollar dbc:Manufacturing_companies_based_in_Dublin_(city) dbr:Rheumatoid_arthritis dbr:CEO dbr:Neuropathy dbr:Phase_III_clinical_trial dbr:Dublin dbr:Crohn's_disease dbr:Chairman dbc:2013_disestablishments_in_Ireland dbr:Immunotherapy dbc:2013_mergers_and_acquisitions dbr:Ziconotide dbr:Phase_II_clinical_trial dbr:Parkinson's_disease dbr:Autoimmunity dbr:County_Westmeath dbr:Semagacestat dbc:Pharmaceutical_companies_disestablished_in_2013 dbc:Companies_formerly_listed_on_the_London_Stock_Exchange dbr:Beta_secretase dbr:Pain dbr:United_States dbr:Amyloid_plaques dbr:New_York_Stock_Exchange dbr:Accounting_scandal dbc:Pharmaceutical_companies_of_Ireland dbc:1969_establishments_in_Ireland dbc:Companies_formerly_listed_on_Euronext_Dublin dbr:Public_company dbc:Pharmaceutical_companies_established_in_1969 dbr:Investor dbr:Don_Panoz dbr:London_Stock_Exchange dbc:Companies_formerly_listed_on_the_New_York_Stock_Exchange dbr:Natalizumab dbr:Inflammatory_bowel_disease dbr:Neurodegeneration dbr:Irish_Stock_Exchange dbr:Alzheimer's_disease dbr:Bapineuzumab dbc:Athlone dbr:Neuropathology dbr:Athlone dbr:Antibody dbr:US_dollar dbr:Neurology dbr:Wyeth dbr:Neurotoxicity
dbo:wikiPageExternalLink
n25:
owl:sameAs
n6:LyvD dbpedia-fa:ایلان_(شرکت_دارویی) freebase:m.02__2g wikidata:Q1324860 dbpedia-sq:Élan n21:10037813-4 dbpedia-de:Elan_Corporation n23:132864368
dbp:wikiPageUsesTemplate
dbt:Use_Irish_English dbt:Other_uses dbt:Infobox_company dbt:Authority_control dbt:! dbt:Short_description dbt:Reflist dbt:Use_dmy_dates
dbo:thumbnail
n18:Elan.png?width=300
dbp:defunct
2013
dbp:fate
Acquired by Perrigo
dbp:foundation
Athlone, County Westmeath, Ireland
dbp:industry
Biotechnology
dbp:keyPeople
Robert Ingram, Chairman Kelly Martin, CEO
dbp:location
Dublin, Ireland
dbp:logo
Elan.png
dbp:netIncome
$ million USD
dbp:operatingIncome
$ million USD
dbp:products
NANOCRYSTAL technology TYSABRI dbr:Ziconotide AZACTAM In pipeline: MAXIPIME for Injection
dbp:revenue
$0.2 million USD
dbp:tradedAs
NYSE:ELN
dbp:type
dbr:Public_company
dbo:abstract
Elan Corporation plc was a major drugs firm based in Dublin, Ireland, which had major interests in the United States. It was listed on the New York Stock Exchange as ELN, the Irish Stock Exchange as ELN.I, and the London Stock Exchange as ELN.L. In 2013, the company merged with Perrigo to form Perrigo Company PLC. Die Elan Corporation war ein irisch-amerikanisches Biotechunternehmen mit 400 Mitarbeiten (Stand 2012); Ende 2007 hatte die Firma 2000 Mitarbeiter. Elan hat sich auf Krankheiten des Zentralnervensystems wie Multiple Sklerose, Alzheimer-Krankheit und Parkinson-Krankheit spezialisiert, stellt aber auch Antibiotika her. Elan kooperierte mit Biogen, dem nach Genentech und Amgen drittgrößten Biotechunternehmen der Welt. Gemeinsam brachten beide Unternehmen 2005 das MS-Medikament Tysabri auf den Markt, mussten dies jedoch aufgrund eines Todesfall bereits nach kurzer Zeit wieder vom Markt nehmen. Nach der Einreichung gemeinsamer Anträgen zum erweiterten Einsatz von Tysabri im Januar 2013 kaufte Biogen für 3,25 Milliarden Dollar seinem Partner Elan dessen 50 %-Anteil an den Tysabri-Rechten ab und beendete das Kooperationsabkommen. Im Bereich der Alzheimer-Forschung arbeitet Elan an Inhibitoren der Gamma- und Beta-Sekretase, welche die Entstehung der Krankheit verhindern könnten. Das Unternehmen ist Mitglied im ISEQ Overall Index an der Irish Stock Exchange. Im Dezember 2013 gab Perrigo den Abschluss der Übernahme von Elan für 8,6 Milliarden US-Dollar bekannt.
gold:hypernym
dbr:Firm
prov:wasDerivedFrom
wikipedia-en:Élan?oldid=1118106166&ns=0
dbo:wikiPageLength
7139
dbo:fate
Acquired byPerrigo
dbo:foundingYear
1969-01-01
dbo:revenue
200000.0
dbo:keyPerson
dbr:CEO dbr:Chairman
dbo:product
dbr:Ziconotide
dbo:type
dbr:Public_company
foaf:isPrimaryTopicOf
wikipedia-en:Élan